gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · XBIOHealthcarePharmaceuticals

Xenetic Biosciences, Inc. (XBIO)

$2.01−3.37%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$2.06▼ 33.97% in range
Nov 3, 2025Low $1.72 · High $4.67Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Xenetic Biosciences closed at $2.01 on Nov 4, down 3.37%, 57.0% below its 52-week closing high. Volume of 10.8K shares was 0.40× its 20-day average (below normal).

Split-adjusted performance: -5.2% over one month, -36.6% over six months, -35.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $660.60K, up 12.0% from a year earlier, with a net margin of -140.7%.

Short interest was 11.0K shares at the Oct 15 settlement, down 14.8% from the prior report (0.5% of float, 1.0 days to cover).

Market cap$4.7M2.3M shares
Revenue · quarter$660.6K+12.0% YoY
Diluted EPS$-0.41—
P/E · TTM—P/S 3.2×
Net margin-140.7%Gross 100.0%
Dividend yieldNone
52-week range1.72 – 4.67−57.0% from high
Volume10.8K0.40× 20-day avg
Volatility · 60d158.5%Annualised
Short % of float0.5%1.0 days to cover
Net cash$6.5MCash $6.5M
Next earnings—Not scheduled
Split-adjusted performance
1W −4.3%1M −5.2%3M −29.5%6M −36.6%YTD −7.4%1Y −35.6%3Y −37.8%5Y −88.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum36
Revenue growth59
Net margin42
Value (low P/E)—
Size8

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short11.0K−14.8% vs prior
Days to cover1.0Settled Oct 15
% of float0.5%
Short vol. 10d40.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
XBIOXenetic Biosciences$2.01−3.37%−36.6%+12.0%−140.7%—$4.7M
TCRTAlaunos Therapeutics$1.80−3.23%−31.6%———$4.6MCompare
AZTRAzitra$0.8157−7.71%−66.7%———$4.9MCompare
APUSApimeds Pharmaceuticals US$2.92−1.68%−85.0%———$4.4MCompare
SKYESkye Bioscience$1.14−6.56%−83.3%———$5.0MCompare
IMNNImunon$0.9070+0.78%−66.5%———$5.1MCompare
DRMADermata Therapeutics$0.8548+0.72%−32.7%———$4.2MCompare
TRAWTraws Pharma$0.2686−11.06%−84.2%−100.0%——$4.1MCompare
PCSAProcessa Pharmaceuticals$1.94−0.26%−29.6%———$5.4MCompare

News about Xenetic Biosciences

All news →

No recent articles focused on Xenetic Biosciences.

Quick answers

What does Xenetic Biosciences do?
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers.
What is XBIO's market cap?
$4.71M, based on the Nov 4 close of $2.01.
Does Xenetic Biosciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of XBIO is sold short?
11.0K shares, 0.5% of float, as of Oct 15, 2026.
What sector is XBIO in?
Healthcare, in the Pharmaceuticals industry.

About Xenetic Biosciences

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

HQ: Framingham, MA2 employeesListed May 16, 2012xeneticbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology